Recently, a meta-analysis comprising 2592 HCC patients by Zhong et al. [18] found that the high expression of CD133 was significantly associated with a range of clinicopathological features, such as low tumor stage, advanced tumor stage, vascular invasion, vascular thrombosis, and poorer survival outcome. The gene discussed is PROM1; the disease is hepatocellular carcinoma.